News2421h
A jab that could protect against HIV for a year at a time
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
STAT11d
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
MIT Technology Review9d
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Managed Healthcare Executive9d
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
AllAfrica on MSN2d
A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major Conference
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...
Fierce Pharma11d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
Healio8d
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
BioSpace4d
Trump Eyes Steep Cuts to CDC HIV Prevention Program
The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
Yearly HIV prevention injection shows promise in clinical trial
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Nasdaq11d
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – – Also at CROI: New PURPOSE 1 Data Showcasing ...